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The related trypanosomatid pathogens, Trypanosoma brucei spp., Trypanosoma cruzi and Leishmania spp.
cause devastating diseases in humans and animals and continue to pose a major challenge in drug devel-
opment. Mitochondrial RNA editing, catalyzed by multi-protein complexes known as editosomes, has
provided an opportunity for development of efﬁcient and speciﬁc chemotherapeutic targets against try-
panosomatid pathogens. This review will discuss both methods for discovery of RNA editing inhibitors, as
well as inhibitors against the T. brucei editosome that were recently discovered through creative virtual
and high throughput screening methods. In addition, the use of these inhibitors as agents that can block
or perturb one or more steps of the RNA editing process will be discussed. These inhibitors can potentially
be used to study the dynamic processing and assembly of the editosome proteins. A thorough under-
standing of the mechanisms and speciﬁcities of these new inhibitors is needed in order to contribute
to both the functional studies of an essential gene expression mechanism and to the possibility of future
drug development against the trypanosomatid pathogens.
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The three major trypanosomatid pathogens, Trypanosoma
brucei, Trypanosoma cruzi and Leishmania major are related para-
sitic protozoa of kinetoplastids, and cause different diseases,
including Human African trypanosomiasis, Chagas disease, andPublished by Elsevier Ltd.
gy, McGill University, 21111
da H9X3V9. Tel.: +1 514 398
i).
Open acLeishmaniasis, respectively. Leishmaniasis reportedly has a mortal-
ity rate of 50,000 individuals per year and annual loss of 2.1 million
disability-adjusted life years (DALYs), followed by sleeping sick-
ness with 48,000 deaths per year (1.5 million DALYs per year)
(WHO, 2002). Chagas disease also causes 15,000 deaths and loss
of 700,000 DALYs annually. The available drugs for these diseases
are not ideal, since they are toxic, costly, and have invasive routes
of administration (Croft et al., 2005; Delespaux and de Koning,
2007; Stuart et al., 2008; Teixeira et al., 2006). Also, resistance
against many of these drugs has already emerged; hence there is
an urgent need for development of new drugs (Buckner et al.,cess under CC BY-NC-ND license.
R. Salavati et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 36–46 371998; den Boer and Davidson, 2006; Olliaro et al., 2005; Wilkinson
et al., 2008).
Since Rob Benne discovered RNA editing in 1986 (Benne et al.,
1986), we have come to learn many details about the mechanisms
and major players involved in this remarkable post-transcriptional
RNA maturation process, including its potential as an effective
anti-trypanosomal drug target. Most mitochondrial mRNAs in
kinetoplastids undergo RNA editing to produce mature and func-
tional mRNAs that are translated into multiple essential compo-
nents of the mitochondrial oxidative phosphorylation system
(Hannaert et al., 2003; Madison-Antenucci et al., 2002). The insectFig. 1. Schematic presentation of RNA editing reactions. RNA editing entails maturation
uridylates (Us) as speciﬁed by small guide RNAs (gRNAs). The speciﬁc proteins involvedstage, procyclic form (PF) T. brucei has a highly active mitochon-
drion (Vickerman, 1965) and generates ATP by oxidative phosphor-
ylation, and hence RNA editing is crucial for its energy metabolism.
Although oxidative phosphorylation is repressed in bloodstream
form (BF), RNA-editing is nevertheless required to maintain an ac-
tive mitochondrion, which is needed for other essential metabolic
pathways such as calcium homeostasis and fatty acid metabolism,
(Hashimi et al., 2010; Schnaufer et al., 2005). Encouragingly, sev-
eral proteins involved in editing process were found to be essential
for the growth and survival of the BF (Baldassarre et al., 2003;
Carnes et al., 2005; Deng et al., 2005; Drozdz et al., 2002; Guoof the mitochondrial mRNAs by insertion (left panel) and deletion (right panel) of
in each catalytic reaction are highlighted.
Table 1
Biological importance and biochemical functions of editosome proteins – alternative nomenclatures are also mentioned (e.g. TbMP63, T. brucei mitochondrial protein of 63 kDa).
Protein Proposed function Essentiality Technique
used for
inhibition
Effects on RNA editing activities and the editosome
complex
References
KREPA1/TbMP81 RNA/protein
interaction
BF and PF RNAi-
mediated
repression
- Inhibition of in vivo RNA editing
- Loss of endoribonuclease, TUTase and RNA
ligase activities associated with insertion
editing
Drozdz et al. (2002)
O’Hearn et al. (2003)
KREPA2/TbMP63 RNA/protein
interaction
PF RNAi-
mediated
repression
- Great reduction in endonuclease activity for
both U deletion and U insertion
- Loss of KREL1
- Disruption of proper editosome assembly
Huang et al. (2002)
KREPA3/TbMP42 RNA/protein
interaction
BF and PF Regulatable
knockout in
BF
RNAi-
mediated
repression
in PF
- Complete loss of editosome in BF
- Reduced RNA editing activity in PF
- Inhibition of endoribonucleolytic cleavage in
both U deletion and U insertion, but other steps
not affected
Brecht et al. (2005), Law et al.
(2008), Guo et al. (2008), Guo
et al. (2010)
KREPA4/TbMP24 RNA/protein
interaction
PF RNAi-
mediated
repression
- Loss of editosome proteins
- Reduction of both U deletion and U insertion
- Reduction of editosome stability and/or inter-
ruption of editosome assembly
Kala and Salavati (2010), Salavati
et al. (2006)
KREPA5/TbMP19 RNA/protein
interaction
N.D. N.D. Carnes et al. (2011), Panigrahi
et al. (2006)
KREPA6/TbMP18 RNA/protein
interaction
PF RNAi-
mediated
repression
- Loss of both U deletion and U insertion
- Loss of the structural integrity of editosome
Tarun et al. (2008)
KREN1/TbMP90 U deletion-speciﬁc
endonuclease
BF and PF RNAi-
mediated
repression
in PF
Regulatable
knockout in
BF
- Inhibition of in vivo editing
- Inhibition of in vitro endoribonucleolytic cleav-
age of deletion substrates; cleavage of insertion
substrates and other catalytic activities of edit-
ing not affected
Kang et al. (2006), Trotter et al.
(2005)
KREN3/TbMP67 Endonuclease speciﬁc
for Cytochrome
oxidase II pre-edited
mRNA
BF Regulatable
knockout
- Elimination of COII RNA editing in vivo
- Inhibition of endonucleolytic cleavage of COII
RNA substrate in vitro
- Editosomes and in vitro catalytic activities
(based on A6 derived RNA substrates) retained
Carnes et al. (2008)
KREN2/TbMP61 Insertion-speciﬁc
endonuclease activity
BF and PF RNAi-
mediated
repression
in PF
Regulatable
knockout in
BF
- Inhibition of in vivo editing in PF and BF
- Inhibition of in vitro cleavage of insertion edit-
ing substrates; cleavage of deletion substrates
and other catalytic activities of editing not
affected
Carnes et al. (2005)
KREPB4/TbMP46 RNA/protein
interaction
PF RNAi-
mediated
repression
- Altered editosome integrity and abundance
- Reduced in vivo RNA editing
- Reduced insertion and deletion endonuclease
activities
Babbarwal et al. (2007)
KREPB5/TbMP44 RNA/protein
interaction
BF Regulatable
knockout
- Loss of editing in vivo
- Loss of editing-associated catalytic activities
in vitro
- Perturbation of the editosome structure
Baldassarre et al. (2003)
KREPB6/TbMP49 RNA/protein
interaction
N.D. N.D. Panigrahi et al. (2006), Carnes
et al. (2011)
KREPB7/TbMP47 RNA/protein
interaction
N.D. N.D. Panigrahi et al. (2006), Carnes
et al. (2011)
KREPB8/TbMP41 RNA/protein
interaction
N.D. N.D. Panigrahi et al. (2006), Carnes
et al. (2011)
KREL1/TbMP52 Deletion-speciﬁc
Ligase
BF Regulatable
knockout
- Complete inhibition of RNA editing Schnaufer et al. (2001), Cruz-
Reyes et al. (2002)
KREL2/TbMP48 Insertion-speciﬁc
Ligase
Not
essential in
BF and PF
RNAi-
mediated
repression
- No effect on RNA editing Drozdz et al. (2002), Gao and
Simpson (2003), Cruz-Reyes
et al. (2002)
KREX1/TbMP100 30–50 exonuclease
responsible for U-
deletion
PF RNAi-
mediated
repression
- Disruption of editosome
- Reduction of KREN1 in editosomes
- Preferential Inhibition of
- In vitro pre-cleaved U-deletion editing
Kang et al. (2005), Rogers et al.
(2007), Ernst et al. (2009)
KREX2/TbMP99 30–50 exonuclease
activity
PF (Minor
effect on
cell
growth)
RNAi-
mediated
repression
- Little effect on editosome stability
- Reductions of KREPA2 and KREL1 in editosomes
- Modest reductions of both insertion and dele-
tion endonuclease activities
- Signiﬁcant reduction of U removal in vitro
Rogers et al. (2007), Ernst et al.
(2009)
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Table 1 (continued)
Protein Proposed function Essentiality Technique
used for
inhibition
Effects on RNA editing activities and the editosome
complex
References
KRET1 Guide RNA-speciﬁc
TUTase
PF RNAi-
mediated
repression
- Reduction of RNA editing
- Accumulation of guide RNA with shorter U tails
Aphasizhev et al. (2002), Ernst
et al. (2003)
KRET2/TbMP57 U insertion-speciﬁc
TUTase
PF RNAi-
mediated
repression
- Complete inhibition of U-insertion in vitro
- No effect on the length of guide RNA oligo(U)
tails
Aphasizhev et al. (2003c), Ernst
et al. (2003)
KREH1/mHel61p Helicase activity PF Knockout - Reduced amounts of edited mRNAs Missel et al. (1997), Li et al.
(2011)
N.D.: not determined.
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2001; Trotter et al., 2005). Therefore, editing is an essential process
in both life stages. This observation suggests the important
possibility that the RNA editing process may provide similar and
efﬁcient chemotherapeutic targets throughout the medically
important trypanosomatid parasites. Furthermore, this type of
RNA editing is unique to these parasites; hence, targeting this
process should have a few or no side effects in the human host.
Here we will review the recent advances in development of new
methods to discover potential inhibitors of RNA editing in T. brucei.
We will also highlight how recently reported inhibitors of RNA
editing may contribute to both the functional studies of this essen-
tial RNA processing mechanism and to the exciting possibility of
future drug development against the three related trypanosomatid
pathogens.
2. RNA editing process
In vitro studies using mitochondrial extract from T. brucei (Seiw-
ert et al., 1996) indicate that RNA editing is mediated by a series of
coordinated catalytic steps of multi-protein complexes known as
editosomes, which insert and delete uridylates (Us) as speciﬁed
by guide RNAs (gRNAs) (Aphasizhev and Aphasizheva, 2011; Blum
et al., 1990; Osato et al., 2009; Simpson et al., 2003, 2000; Sturm
and Simpson, 1990). The initial event in the editing reaction is
hybridization of the 50 end of the gRNA to the precursor mRNA
(pre-edited mRNA) just downstream of the ﬁrst editing site, to
form an anchor duplex (Blum et al., 1990). The catalytic cascade
of RNA editing occurs by endonucleolytic cleavage of the precursor
mRNA at the editing site, U addition by 30-terminal uridylyl trans-
ferase (TUTase) activity or removal by 30 exouridylylase activity
(exoUase) both at the 30 end of the 50 cleavage fragment, and sub-
sequent ligation of the RNA fragments by RNA ligase activity, re-
viewed in (Hajduk and Ochsenreiter, 2010; Stuart et al., 1997)
(Fig. 1). In addition, the editosome contains RNA editing-associated
RNA helicase activity, which may affect gRNA/mRNA interactions
and/or displace gRNA after its use (Missel et al., 1997).
RNA editing appears to involve dynamic interactions of multiple
proteins and complexes that are not directly part of the core edito-
some, but indirectly regulate the efﬁciency of editing and edito-
some stability. For example, the MRP complex, which consists of
MRP1 and MRP2 proteins, has a matchmaking type of RNA anneal-
ing activity (Muller and Goringer, 2002; Schumacher et al., 2006;
Zikova et al., 2008). RBP16 also plays a role in gRNA/pre-mRNA
interaction and has been shown to have an overlapping function
with MRP1 and MRP2 proteins (Ammerman et al., 2008; Fisk
et al., 2009). The mitochondrial RNA binding complex 1 (MRB1)
or the guide RNA binding complex (GRBC), which share a number
of common protein components and likely represent the same par-
ticle, have recently been described to play a role in diverse aspects
of mitochondrial RNA metabolism such as gRNA utilization andexpression and/or stability of gRNAs as well as edited and pre-edi-
ted mRNAs (Acestor et al., 2009; Ammerman et al., 2008, 2011,
2010; Hashimi et al., 2009, 2008; Hernandez et al., 2010; Panigrahi
et al., 2008; Weng et al., 2008).
3. The editosome composition
The functional editosome proteins were identiﬁed by several
methods including mass spectrometric analysis of editosomes that
were puriﬁed by serial ion exchange and gel permeation chroma-
tography, immunoafﬁnity chromatography speciﬁc to editosome
proteins, or tandem afﬁnity puriﬁcation (TAP) based on tagged
RNA editing proteins (Aphasizhev et al., 2003a; Panigrahi et al.,
2006, 2001a,b, 2003; Rusche et al., 1997). Several nomenclatures
have been proposed in literature to describe the editosome pro-
teins (Panigrahi et al., 2001a; Peris et al., 1997; Rusche et al.,
1997; Simpson et al., 2010; Stuart et al., 2005). Here we will use
the nomenclature proposed by Stuart et al., with Kinetoplastid
RNA editing (KRE) as preﬁx followed by abbreviation for its func-
tion if experimentally known (Stuart et al., 2005). The letter K will
be replaced with species’ abbreviation when speciﬁcally discussed
throughout this article. Proteins that catalyze exoUase (KREX1 and
KREX2) (Ernst et al., 2009; Kang et al., 2005; Rogers et al., 2007),
TUTase (KRET2) (Aphasizhev et al., 2003c; Ernst et al., 2003), ligase
(KREL1 and KREL2) (McManus et al., 2001; Rusche et al., 2001;
Schnaufer et al., 2001), endonuclease (KREN1, KREN2, and KREN3)
(Carnes et al., 2005, 2008; Trotter et al., 2005), and helicase
(KREH1) (Li et al., 2009; Missel et al., 1997) activities of editing
have been identiﬁed and functionally characterized (Fig. 1). The
number of proteins in the fully functional editosome is not known;
however, the most recent studies have identiﬁed around 20 pro-
teins (Table 1) as highly dynamic components of three complexes,
all with a common set of core proteins, but each associated with a
different endonuclease (KREN1–3) (Carnes et al., 2011, 2008;
Panigrahi et al., 2006; Trotter et al., 2005). These complexes sedi-
ment at  20 Svedberg (20S) on glycerol gradients and hence are
known as ‘20S editosome’ (Carnes et al., 2008; Panigrahi et al.,
2006). These editosomes may represent a ‘‘catalytic core complex’’
and additional proteins may contribute to RNA editing in vivo. Mul-
ti-subunit complexes comprised of separate insertion and deletion
activities each sedimenting at 5–10S have also been proposed
which may contribute to the assembly of the entire system
(Schnaufer et al., 2003). Whether editosomes contain catalytic or
structural RNA is unknown.
The editosome proteins are related in pairs or sets by sequence
and motif similarities which reﬂect their functions with predicted
catalytic and/or RNA interaction motifs (Worthey et al., 2003). For
instance, the two editosome RNA ligases are similar (41% identity)
and several lines of evidence have suggested that KREL1 is involved
in U-deletion editing and KREL2 is involved in U-insertion editing,
leading to the proposed structural and functional division of the
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(Schnaufer et al., 2003). KREPA1–6 are six additional editosome
proteins which share a C-terminal motif associated with an oligo-
nucleotide-binding (OB) fold with varying degrees of relatedness
(Worthey et al., 2003). The largest three of these ﬁve proteins also
have C2H2 zinc ﬁnger motifs, suggesting possible RNA/protein-
binding functions. The speciﬁc functions of these six proteins are
not yet known; however, recent data propose extensive protein–
protein interactions that are mediated by OB-fold proteins, coordi-
nating the editosome function (Schnaufer et al., 2010).4. Editosome as drug target
Gene inactivation studies of RNA editing ligase 1 in T. brucei
(TbREL1) showed for the ﬁrst time that RNA editing is essential
in BF (Schnaufer et al., 2001). Subsequent RNAi mediated repres-
sion and gene knockout studies of several functionally character-
ized editosome proteins has shown that RNA editing is essential
in both life cycle stages of the parasite (Table 1). It should be men-
tioned that there are ‘‘dyskinetoplastic’’ trypanosomes that have
partially lost their kinetoplast (Brun et al., 1998), in which the
RNA editing process has been suggested to be dispensable. For
example, it has been shown that in the dyskinetoplastic Trypano-
soma evansi, although editosome proteins are expressed and even
imported into the mitochondrion, their function is not essential
(Paris et al., 2011). This loss of essentiality has been hypothesized
to be the result of a compensatory mutation in a nuclear-encoded
subunit of the mitochondrial ATP synthase (Lai et al., 2008;
Schnaufer et al., 2005, 2002). Therefore, drugs targeting RNA edit-
ing machinery will likely not work against dyskinetoplastic para-
sites of livestock, such as T. evansi and T. equipedrum. However,
as mentioned before, RNA editing is essential in all known trypan-
osomatid parasites of human, including the closely related T. bru-
cei, T. cruzi and Leishmania spp. Therefore, RNA editing is a viable
drug target, indicating the need for development of methods for
discovery of new chemical compounds that can inhibit this pro-
cess. In the next sections, we will discuss such methods and the
compounds that have been discovered.5. High-throughput screening (HTS) methods: virtual and
chemical
In this review, we have chosen to focus our attention on the dis-
covery and development of innovative therapeutic agents that tar-
get RNA editing. Target-driven approaches can identify chemicals
that speciﬁcally affect a certain biological process with minimal
off-targets effects (Ilag et al., 2002; Westwell and Stevens, 2004).
Identiﬁcation of validated and druggable biological targets with
essential roles in the cell is the ﬁrst step towards target-driven
drug discovery. The target can be a speciﬁc protein with an essen-
tial function, such as TbREL1. Alternatively, an essential protein
complex or biological process can be considered as the target, such
as the whole editosome. In this case, the drug discovery process is
unbiased towards a speciﬁc protein, and the chances of identifying
an effective compound are higher. The second step consists of a
‘‘molecule hunt’’ which involves HTS of libraries of small-molecule
compounds in order to identify a hit. Modern approaches such as
combinatorial chemistry, structural biology and computational
analysis can be leveraged to increase the chances of success in this
step and minimize the required time. The next step is known as
hit-to-lead development, with the aim of identifying a lead com-
pound with drug-like properties that is active in the cellular con-
text. Lastly, the lead development step will test and optimize the
pharmacokinetic and pharmacodynamic properties of the lead
compounds in vivo, towards the identiﬁcation of a clinical candi-date. In this section, we will focus on recent developments on vir-
tual and chemical screening of libraries towards identiﬁcation of
chemical compounds that target the editosome.
5.1. Virtual screening methods
Virtual screening emerged as an important tool for the discov-
ery of drug-like compounds against a speciﬁc target (Kuntz,
1992; Maryanoff, 2004; Shoichet, 2004; Shoichet et al., 2002; Var-
ney et al., 1992; von Itzstein et al., 1993). Currently, various proto-
cols are available for virtual screening of chemical compound
databases. Overall, virtual screening contains the following two
steps: (i) rapid docking algorithms are used in order to identify
the most likely position and orientation of the available candidate
compounds within the active site of protein of interest; (ii) the
compound activity is ranked by analyzing the steric and electro-
static properties of the predicted protein–ligand complex (Reddy
et al., 2007). This approach has been used recently (Amaro et al.,
2008; Durrant et al., 2010; Moshiri et al., 2011) in order to ﬁnd po-
tential drug-like compounds against TbREL1, one of the essential
enzymes of the editosome whose N-terminal high-resolution crys-
tal structure is available (Deng et al., 2004). Moreover, there are no
close human homologs; hence, TbREL1 can be used as an ideal che-
motherapeutic target for designing selective inhibitors that block
the essential RNA ligase function.
The ligation mechanism of TbREL1 is similar to that of DNA li-
gases, although their structures are different. The ligation reaction
follows three steps (Fig. 2): (i) the adenylylation step, in which the
conserved catalytic lysine attacks a-phosphate of ATP and releases
pyrophosphate. At this step, an enzyme-AMP intermediate is
formed through the phosphoamide linkage; (ii) The deadenylyla-
tion step, in which TbREL1-AMP can recognize the double-stranded
nicked mRNA/gRNA and transfer its bound AMP to the 50-phos-
phate of the RNA molecule, forming an adenylylated RNA with a
50,50-phosphoanhydride bond; (iii) The ligation step, in which the
free 30-hydroxyl of the 50 fragment attacks the phosphoanhydride
bond of the adenylylated 30 RNA fragment at the nick site, leading
to the formation of phosphodiester bond and the release of AMP.
Recent studies have performed virtual screening of various
compounds against high-resolution structure of TbREL1 in order
to identify compounds that can inhibit the adenylylation step by
competing with ATP for the active site. In the ﬁrst study, Amaro
et al. (2008) initially used structure-based virtual screening of a li-
brary of compounds from National Cancer Institute (NCI) to iden-
tify the top compounds with the highest binding afﬁnity. This
resulted in a set of drug-like candidate compounds, named V1 to
V8. Since these compounds were predicted to bind to the ATP-
binding pocket of TbREL1, their effect on TbREL1 adenylylation
was tested experimentally; V1 and V4 showed the highest inhibi-
tion of the adenylylation step among the candidates. Amaro et al.
then used a ligand-based virtual screening, in which they searched
for compounds with the highest similarity to V1. They came up
with six more compounds that were predicted to have very high
afﬁnity for TbREL1 ATP-binding pocket, named S1 to S6, among
which S5 was shown experimentally to have the highest inhibitory
effect on TbREL1 (Table 2). These drugs were reported to have an
in vitro effect on the adenylylation step, although they did not
show any phenotypic effect on the cultured T. brucei cells, most
probably because the cells were not permeable to these com-
pounds. Furthermore, their inhibitory effect on TbREL1 and the clo-
sely related T4 RNA ligase 2 in comparison to human DNA ligase III
suggests selectivity for RNA ligases. Later, in another study, Dur-
rant et al. performed virtual screening against TbREL1 using a li-
brary of compounds that were similar to the core naphthalene
scaffold of previously found TbREL1 inhibitors, resulting in four no-
vel compounds named V1 to V4 (Durrant et al., 2010). Among these
Fig. 2. The schematic presentation of the three-step ligation mechanism of RNA editing ligase 1.
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step most efﬁciently, and V4 was able to kill the parasite as well.
Simultaneously, Moshiri et al., performed structure-based virtual
screening against TbREL1 (Moshiri et al., 2011), resulting in 12 po-
tential inhibitors of TbREL1 adenylylation, of which one was shown
experimentally to inhibit full-round RNA editing reaction. This
compound, named C35, turned out to be the same as the com-
pound V2 found by Durrant et al. while Moshiri et al. performed
the docking on a single protein conformation based on the avail-
able crystal structure of TbREL1, Durrant et al. used the ‘‘relaxed
complex scheme’’, in which the compounds were docked on an
ensemble of 30 protein conformations obtained from molecular
dynamic simulations.
According to these studies, the predicted binding mode of C35
(V2) (Durrant et al., 2010; Moshiri et al., 2011) is as follow: theo-
retically, the interaction of this compound with TbREL1 mimics
certain aspects of ATP binding. Similar to the adenine moiety of
ATP, one of the naphthalene rings of C35 forms a p–p stacking
interaction with Phe209. Also, similar to the triphosphate tail of
ATP, a sulfonate group forms an ion pair with the guanidine group
of Arg111. Aminonaphthyl group forms a water-mediated interac-
tion with Arg288 similar to the N1 atom of the adenine moiety in
ATP. While this inhibitor is predicted to bind in the deep binding
pocket of the active site, the study by Durrant et al. revealed a no-
vel predicted drug binding site on the periphery of the TbREL1 ac-
tive site, which can potentially be harnessed to design speciﬁc
inhibitors, given the low similarity of this region with its counter-
part in human DNA ligase.
Drug discovery relies on experimental validation for identiﬁca-
tion of compounds with real inhibitory effect on the target. In the
next section, we will discuss methods for validation of computa-
tionally identiﬁed chemicals, as well as for direct discovery of
inhibitory compounds from chemical compound libraries.
5.2. Chemical HTS methods
In order to design a successful high-throughput screening assay,
several factors should be taken into consideration. For example,sensitivity, speciﬁcity and reproducibility of the assay [collectively
measured by an important statistical parameter called the Z-factor
(Zhang et al., 1999)], manageability of the compound library, and
suitability of reagents for large-scale screening are among the most
important factors in order to develop a successful HTS assay. Two
types of HTS assays can be developed; homogeneous assays and
heterogeneous assay. Homogeneous assays are simpler and include
straightforward steps such as addition of reagents, incubation, and
reading, whereas heterogeneous assays are more cumbersome due
to their requirement for extra steps such as several washing steps,
ﬁltration, and centrifugation. Hence, an ideal HTS assay should be
homogenous, inexpensive, with minimal requirement for complex
instrumentation.
Recently, two HTS assays were designed and developed for
screening of different chemical libraries against the editosome
(Fig. 3) (Liang and Connell, 2009; Moshiri and Salavati, 2010). Liang
et al. developed a heterogeneous RNA aptamer-based assay in
which RNA editing reaction can be monitored using electroche-
miluminescent signal. In this study, upon successful U-insertion
RNA editing, the RNA aptamer undergoes a conformational change
that activates its streptavidin-binding region, resulting in a mea-
surable electrochemiluminescent signal. In another study by
Moshiri et al., a simple ‘mix and measure’ homogeneous HTS assay
based on ﬂuorescence resonance energy transfer (FRET) has been
developed. This assay uses hammerhead ribozyme as an RNA edit-
ing substrate. Upon successful U-deletion RNA editing, the inactive
ribozyme becomes active and is able to cleave a 16-nucleotide
FRET substrate that carries a ﬂuorescent reporter (FAM) on the 50
end and a quencher (TAMRA) on the 30 end, resulting in a detect-
able signal. While these two methods monitor the activity of the
whole editosome in the context of U-deletion and U-insertion
RNA editing, novel methods are being developed that can speciﬁ-
cally monitor the ligase activity of TbREL1 (Hall and Schnaufer,
Kinetoplastid Molecular Cell Biology meeting, 2011). The availabil-
ity of these different methods provides the opportunity to ﬁnd
inhibitors against a wide range of RNA editing-related activities.
In the next section, we will describe the recently found inhibitors
of RNA editing based on these assays as well as virtual screening.
Table 2
The most potent inhibitors of RNA editing and their possible mode of action.
ID/source Structure IC50 (lM) based on
adenylylation
activity
IC50 (lM) based on
full-round RNA
editing activity
Potential mode of
inhibition
References
V4, Sigma Mordant
Black 25
1.59 ± 1.10 N.D. Adenylylation Durrant et al. (2010)
C35/V2, NSC162535 1.53 ± 1.17 N.D. Deadenylylation/
adenylylation/RNA–
protein interaction
Durrant et al. (2010),
Moshiri et al. (2011)
V1, NSC45609 2.16 ± 1.20 N.D. Adenylylation Durrant et al. (2010)
V3, NSC1698 8.36 ± 1.71 N.D. Adenylylation Durrant et al. (2010)
S5, NSC16209 1.01 ± 0.16 2.1 ± 0.4 Deadenylylation/
adenylylation/RNA–
protein interaction
Amaro et al. (2008),
Moshiri et al. (2011),
Moshiri and Salavati
(2010)
S1, NSC100234 1.95 ± 0.61 N.D. Adenylylation Amaro et al. (2008)
NF023 N.D. 2.9 ± 0.7 RNA editing before or at
the endonuclease cleavage
step/global effect on
editing complex
Liang and Connell
(2010)
Mitoxantrone N.D. 2.6 ± 0.5 RNA editing before or at
the endonuclease cleavage
step/global effect on
editing complex
Liang and Connell
(2010)
D-Sphingosine N.D. 2.0 ± 0.1 RNA editing after the
endonuclease cleavage
step/global effect on
editing complex
Liang and Connell
(2010)
42 R. Salavati et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 36–46
Table 2 (continued)
ID/source Structure IC50 (lM) based on
adenylylation
activity
IC50 (lM) based on
full-round RNA
editing activity
Potential mode of
inhibition
References
GW5074 N.D. 2.9 ± 0.4 RNA editing before or at
the endonuclease cleavage
step
Liang and Connell
(2010)
Protoporphyrin IX N.D. 0.9 ± 0.1 RNA editing before or at
the endonuclease cleavage
step
Liang and Connell
(2010)
N.D.: not determined.
Fig. 3. RNA editing assays that are developed for high-throughput screening – Left panel illustrates the RNA aptamer-based assay. In this assay, an aptamer that is labeled
with ruthenium (red ball) is used, which upon successful addition of three Us changes conformation and, becomes activated, and thus binding to the streptavidin that coats
the microtiter plate. Upon electrical stimulation, the ruthenium complex generates a measurable ECL signal. Right panel illustrates the FRET-based assay, in which the 16nt-
long reporter RNA is labeled with a ﬂuorescent reporter (FAM, red ball) and a ﬂuorescent quencher (TAMRA, blue ball). In this assay, upon successful deletion of three Us from
the catalytic core of HHR, the inactive HHR becomes active and cleaves the reporter RNA and generates a detectable ﬂuorescent signal. (For interpretation of reference to
colors in this ﬁgure legend, the reader is referred to the web version of this article.)
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Liang et al. used their aptamer-based assay to screen a library of
pharmacologically active compounds (LOPAC) against RNA editing
machinery, and found 28 hits with strong inhibitory effect on RNA
editing (Liang and Connell, 2010). By performing secondary assays,
two of the compounds were found to perturb endonuclease activ-
ity at the initial steps of RNA editing process (Table 2). While Lianget al. used the whole editosome as the initial target for drug discov-
ery, the Amaro group as well as the Salavati group used the essen-
tial TbREL1 as a speciﬁc target to screen several chemical
compounds for inhibitors of RNA editing. The Amaro group identi-
ﬁed several naphthalene-based compounds through virtual screen-
ing, and reported inhibitory effect of these compounds on the
adenylylation step of ligation in vitro using recombinant TbREL1
(Table 2). Two of these compounds, namely S5 and C35 (V2), were
44 R. Salavati et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 36–46later tested by the Salavati group on whole editosome, and showed
strong inhibition of U-deletion RNA editing (Moshiri et al., 2011).
Secondary assays conﬁrmed that this compound could inhibit the
adenylylation of TbREL1 at very low editosome concentrations,
whereas at higher editosome concentration, which is required for
obtaining full-round RNA editing, the deadenylylation of TbREL1
was inhibited, but not adenylylation. Moshiri et al. thus suggested
that although these compounds are able to inhibit adenylylation of
TbREL1, this might not be the mechanism through which the drug
exerts its effect in the functional biological context (Moshiri et al.,
2011). Based on the observation that these compounds inhibited
all editing steps that required RNA–editosome interaction, Moshiri
et al. suggested that C35 and S5 inhibit the interaction of the edi-
tosome with its substrate RNA, and supported their claim by di-
rectly examining the effect of these compounds on RNA–
editosome interaction. Consistent with these observations, C35
addition could also alter the sedimentation proﬁle of the 20S edi-
tosomes which most likely results from direct perturbation of
RNA–protein interactions and the editosome assembly and/or
integrity. These observations highlight the potential use of such
compounds and their importance in the better understanding of
TbREL1-inhibitor interaction and editosome assembly. Taken to-
gether, these naphthalene-based compounds appear to ﬁnd addi-
tional targets other than the anticipated ATP-binding pocket of
TbREL1 in the context of partially puriﬁed functional editosomes.
These studies raise a few essential questions with respect to naph-
thalene-based inhibitors-TbREL1 interaction; do the inhibitors
bind similar or distinct targets? Do the interactions of inhibitors af-
fect TbREL1 sub-complex assembly and/or stability, or do they
block recruitment of the editing substrates to the editosome?
Studying the mechanistic details of inhibition of TbREL1 activity
by these compounds will not only provide valuable insights to
the editosome assembly, but will be instrumental in determining
the mode of action and designing more effective inhibitors of the
editosome.
7. Conclusion and prospects
Although recent studies have provided much insight on the
structure of editosome (Golas et al., 2009; Li et al., 2009), the
mechanism and sequence of editosome assembly is largely un-
known. Acting as an editosome subunit, a gRNA–protein complex
may bring gRNA to the editosome; however, this has yet to be con-
ﬁrmed (McManus et al., 2000). In several studies, it has been
shown that treatment of editosome complex with nucleases results
in disassembly of complex and loss of editing activities, suggesting
a role for RNA to maintain the editosome complex integrity (Apha-
sizhev et al., 2003b; Salavati et al., 2002). On the other hand, it has
been reported that mutants that lack mitochondrial DNA and,
hence, lack mitochondrial mRNA and gRNA contain catalytically
active editosomes (Domingo et al., 2003). These data suggest mito-
chondrial encoded RNA may not be required for assembly of func-
tional editosomes. Therefore, it is not known whether RNA editing
is catalyzed by an editosome that is formed by the association of
multi-subunit complexes upon RNA binding, similar to the ribo-
some, or it is rather with the RNAs in a stepwise manner and with
discrete intermediates, similar to the spliceosome (Hoskins et al.,
2011). Asides from their use as chemotherapeutic agents, small
compounds have provided a wealth of information regarding the
conformational dynamics of ribosome. For instance, paromomycin,
puromycin, erythromycin, and viomycin, have been quite useful in
helping to understand ribosomal function and assembly, its recog-
nition of tRNAs, and translation by trapping the ribosome in an
intermediate state (Douthwaite et al., 1985; Ermolenko et al.,
2007; Moazed and Noller, 1989; Yoshizawa et al., 1999). Similarly,compounds identiﬁed against the spliceosome have allowed a dee-
per understanding of the assembly of the functional spliceosome
by blocking various stages of assembly with some possessing anti-
tumor activities (Albert et al., 2007; Kaida et al., 2007; Kotake et al.,
2007; O’Brien et al., 2008). We anticipate that the chemical com-
pounds generated from the high throughput screening against
the editosome will block or otherwise affect one or more steps in
the editing cycle. These steps include potentially various stages
of the editosome assembly, leading to the initiation of the catalytic
steps, editing of multiple sites with the use of multiple gRNAs, and
a termination step. Due to multi-subunit nature of the editosome
which may involve assembly of such units, we may ﬁnd the chem-
ical genetics approach more advantageous compared to RNAi or
gene replacement strategies, interfering with the editosome func-
tion and assembly by direct editosome binding. The characteristics
of the alterations will indicate likely functions for speciﬁc compo-
nents of the editosome proteins and their order of assembly. Thus,
development and characterization of editosome inhibitors will not
only provide opportunities for possible therapeutics, but also tools
for studying the details of editosome assembly and function.References
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